Abstract: A method or system uses de-identified images collected from patients in association with de-identified data collected as part of medical care to train machine learning, machine vision, deep learning, or other algorithms that associate an outcome variable with an input image or video image(s).

Abstract: Systems and methods include a computer-implemented method for determining a diagnosis based on audio-visual information from a monitored person. A subject is monitored using one or more video systems. Vital health information of the subject is determined based at least on the monitoring. At least one diagnosis of the subject is determined based at least on the determined vital health information.

Abstract: This document describes methods and materials for improving patient monitoring. For example, this document describes methods and devices for reducing the risk of respiratory arrest, cardiac arrest, brain damage, and/or death by performing audiovisual detection of respiration, heart rate, oxygen saturation, perfusion, blood pressure, and/or motion.

Abstract: Systems and methods provide audio-visual distraction to a patient while the patient is undergoing a surgical or other such medical procedure. When used in the context of a surgical procedure, local anesthetics are used to eliminate the pain of the procedure, autonomic blockade (beta blockers and/or alpha-2 agonists) is used to control autonomic responses, and audio-visual distraction is provided to distract the patient. The system allows reduction in the need for pharmacologic sedation.

Abstract: Systems and methods provide audio-visual distraction to a patient while the patient is undergoing a surgical or other such medical procedure. When used in the context of a surgical procedure, local anesthetics are used to eliminate the pain of the procedure, autonomic blockade (beta blockers and/or alpha-2 agonists) is used to control autonomic responses, and audio-visual distraction is provided to distract the patient. The system allows reduction in the need for pharmacologic sedation.

Abstract: A stable aqueous suspension of water-soluble polyacrylamide particles is in a saturated solution of an ammonium salt. The polyacrylamide particles are characterized by a particle size of about ?150 mesh, and preferably ?270 mesh, with ?400 mesh most preferred. The suspension is at least about 2.5% by weight polyacrylamide. When the ammonium salt is ammonium sulfate, PAM concentrations as high as about 15% by weight can be achieved while still being easily flowable. The suspension is made by stirring the small particle PAM into the saturated ammonium salt solution. The PAM can be quickly dissolved to form a less concentrated PAM solution by adding the suspension to water or to a dilute solution, which can include calcium salts or other soil enhancers.

Abstract: A method of producing an aqueous solution of water-soluble polyacrylamide (PAM) with a concentration of at least about 5 grams per liter includes the steps of providing a monovalent or divalent cation salt solution, and preferably a calcium salt solution, and adding water-soluble PAM particles to the salt solution such that the PAM particles are essentially all dissolved within about 10 seconds. The PAM particles are characterized by a particle size that is about −100 mesh and consisting essentially of molecules having a molecular weight of at least about 15 million a.u. Preferably, the small PAM particles are produced by a mill that produces bulk quantities of small dry, flowable PAM particles from larger commercial grade particles. Small PAM particles produced in such a mill are essentially all soluble in plain water within about 10 seconds. After solution, the polymer concentrate can be diluted with water to make stock solutions of the polymer for some purposes.

Abstract: A method of producing an aqueous solution of water-soluble polyacrylamide (PAM) with a concentration of at least about 5 grams per liter includes the steps of providing a monovalent or divalent cation salt solution, and preferably a calcium salt solution, and adding water-soluble PAM particles to the salt solution such that the PAM particles are essentially all dissolved within about 10 seconds. The PAM particles are characterized by a particle size that is about −100 mesh and consisting essentially of molecules having a molecular weight of at least about 15 million a.u. Preferably, the small PAM particles are produced by a mill that produces bulk quantities of small dry, flowable PAM particles from larger commercial grade particles. Small PAM particles produced in such a mill are essentially all soluble in plain water within about 10 seconds. After solution, the polymer concentrate can be diluted with water to make stock solutions of the polymer for some purposes.

Abstract: Determining the cardiac output of a patient uses first and second electrodes disposed with the peri-aortic adventitia or fat pad of the patient. Third electrode is disposed on the cardiac atrial area of the patient. Fourth electrode is placed either externally on the body surface or internally superior to electrodes one and two. A bioelectrical impedance recorder is coupled to the third and fourth electrodes to pass a current between the electrodes. A bioimpedance recorder is coupled to the first and second electrodes to measure the resulting voltage. The output of the bioelectrical impedance recorder is processed to compute a metric corresponding to the patient's cardiac output. The third electrodes are adapted to be the cardiac pacing electrodes.

Abstract: A stable aqueous suspension of water-soluble polyacrylamide particles is in a saturated solution of an ammonium salt. The polyacrylamide particles are characterized by a particle size of about −150 mesh, and preferably −270 mesh, with −400 mesh most preferred. The suspension is at least about 2.5% by weight polyacrylamide. When the ammonium salt is ammonium sulfate, PAM concentrations as high as about 15% by weight can be achieved while still being easily flowable. The suspension is made by stirring the small particle PAM into the saturated ammonium salt solution. The PAM can be quickly dissolved to form a less concentrated PAM solution by adding the suspension to water or to a dilute solution, which can include calcium salts or other soil enhancers.

Abstract: A method of producing an aqueous solution of water-soluble polyacrylamide (PAM) with a concentration of at least about 5 grams per liter includes the steps of providing a monovalent or divalent cation salt solution, and preferably a calcium salt solution, and adding water-soluble PAM particles to the salt solution such that the PAM particles are essentially all dissolved within about 10 seconds. The PAM particles are characterized by a particle size that is about −100 mesh and consisting essentially of molecules having a molecular weigtht of at least about 15 million a.u. Preferably, the small PAM particles are produced by a mill that produces bulk quantities of small dry, flowable PAM particles from larger commercial grade particles. Small PAM particles produced in such a mill are essentially all soluble in plain water within about 10 seconds. After solution, the polymer concentrate can be diluted with water to make stock solutions of the polymer for some purposes.

Abstract: Improvement in the physical properties of soil is achieved by the application of aqueous mixtures of agricultural polyelectrolytes and polysaccharides to the soil. The combination of agricultural polyelectrolytes and polysaccharides results in greatly improving the physical properties of the soil while significantly reducing the quantity of agricultural polymers as compared to methods of the prior art.